Archibald CP et al. Evidence for a sexually transmitted cofactor for AIDS-related Kaposi's sarcoma in a cohort of homosexual men. Epidemiol 3: 203-209, 1992.

Ascherl G et al. Infection with HIV-1 increases expression of vascular endothelial cell growth factor in T cells: implications for AIDS-associated vasculopathy. Blood 93: 4232-4241, 1999.

Atkinson JO et al. The incidence of Kaposi sarcoma among injection drug users with AIDS in the United States. J Acquir Immune Defic Syndr 37: 1282-1287, 2004.

Baldewag T. et al. Kaposi's sarcoma and protection from HIV dementia: response. Science 280: 362, 1998.

Bary M et al. Heterosexual transmission of the aetiological agent of Kaposi's sarcoma. Lancet 337: 234, 1991.

Bennett CL et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 18: 460-465, 1998.

Beral V et al. Epidemiology of Kaposi's sarcoma. Cancer Surveys 10: 5-22, 1991.

Beral V et al. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335: 123-128, 1990.

Beral V et al. Risk of Kaposi's sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS. Lancet 339: 632-635, 1992.

Biggar RJ et al. Mucosal shedding of human herpesvirus 8 (correspondence). New England Journal of Medicine 344(9): 690-692, 2001.

Blauvelt A et al. Primary human herpesvirus type 8 (HHV-8) infection occurs following adolescence in the United States. Journal of Acquired Immune Deficiency Syndromes 14(4): A35, 1997.

Bobroski L et al. Presence of HHV 8 in the sperm of HIV-1 infected individuals. Journal of Acquired Immune Deficiency Syndromes 14(4): A23, 1997.

Bodsworth N et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. American Journal of Clinical Dermatology 2(2): 77-87, 2001.

Boente P et al. Local peri-lesional therapy with rGM-CSF for Kaposi's sarcoma. Lancet 341(8853):1154, 1993.

Bonhomme L et al. Treatment of AIDS-associated Kaposi's sarcoma with oral tretinoin. American Journal of Hospital Pharmacology 51(19): 2417-2419, 1994.

Boshoff C et al. AIDS associated tumors and HHV-8. Journal of Acquired Immune Deficiency Syndromes 14(4): A18, 1997.

Boshoff C et al. Kaposi's sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet 345: 1043-1045, 1995.

Bourboulia D et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpes virus immune responses and viraemia. AIDS 18: 485-493, 2004.

Brewster DH et al. Epidemiology of Kaposi's sarcoma in Scotland, 1976-1996. British Journal of Cancer 79(11-12): 1938-1942, 1999.

Brodt HR et al. Kaposi' s sarcoma in HIV infection: impact on opportunistic infections and survival. AIDS 12(12): 1475-1481, 1998.

Buchbinder SP et al. Combination antiretroviral therapy and incidence of AIDS-related malignancies. Journal of Acquired Immune Deficiency Syndromes 21(suppl 1): S23-26, 1999.

Calabro ML et al. Detection of Human Herpesvirus 8 in cervicovaginal secretions and seroprevalence in human immunodeficiency virus type 1-seropositive and -seronegative women. Journal of Infectious Diseases 179(6): 1534-1537, 1999.

Campbell TB et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 14(14): 2109-2116, 2000.

Cannon MJ et al. Risk factors for Kaposis sarcoma in men seropositive for both human herpes virus 8 and human immunodeficiency virus. AIDS 17: 215-222, 2003.

Casper C et al. Correlates of prevalent and incident Kaposi's sarcoma-associated herpesvirus infection in men who have sex with men. Journal of Infectious Diseases 185(7): 990-993, 2002.

Casper C et al. Differential reduction of human herpesvirus 8 oropharyngeal shedding rats with specific antiretroviral agents. Eleventh Conference on Retroviruses and Opportunisitic Infections, San Francisco, abstract 780, 2004.

Cesarman E et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. New England Journal of Medicine 332: 1186-1191, 1995.

Chak L et al. Radiation therapy for acquired immunodeficiency syndrome-related Kaposi's sarcoma. Journal of Clinical Oncology 6: 863-867, 1988.

Chang Y et al. Identification of new human herpes virus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865-1869, 1994.

Chu S et al. AIDS in bisexual men in the United States: epidemiology and transmission to women. American Journal of Public Health 82(2): 220-224, 1992.

Cianfrocca M et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. Journal of Clinical Oncology 20(1): 153-159, 2002.

Costagliola D et al. Can antiviral agents decrease the occurrence of Kaposi's sarcoma? (letter). Lancet 246: 579, 1995.

Couturier E et al. Kaposi's sarcoma as a sexually transmitted disease. Lancet 335: 1105, 1990.

Darrow WW et al. Kaposi's sarcoma and exposure to faeces (letter). Lancet 339(8794): 685, 1992.

De Wit R et al. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet 2(8622): 1214-1217, 1988.

Diamond C et al. Seroepidemiology of human herpesvirus 8 among young men who have sex with men. Sexually Transmitted Diseases 28(3): 176-183, 2001.

Dupin N et al. Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet 345: 761-762, 1995.

Dupin N et al. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma. British Journal of Dermatology 140(5): 875-881, 1999.

Duvic M et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase I and 2 trials. Archives of Dermatology 136(12): 1461-1469, 2000.

Elford J et al. Kaposi's sarcoma as a sexually transmissible infection: an analysis of Australian AIDS surveillance data. AIDS 7: 1667-1671, 1993.

Engels EA et al. Cancers associated with Kaposi's sarcoma (KS) in AIDS: a link between KS herpesvirus and immunoblastic lymphoma. British Journal of Cancer 85(9): 1298-1303, 2001.

Ensoli B et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345: 84-86, 1990.

Epstein J et al. Treatment of oral Kaposi sarcoma with intralesional vinblastine. Cancer 71(5): 1722-1725, 1993.

Evans SR et al. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposis sarcoma: an AIDS clinical trials group clinical study. Journal of Clinical Oncology, 20(15): 3236-3241, 2002.

Figg WD et al. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 17(1): 91-97, 1997.

Fischl MA et al. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. Journal of Acquired Immune Deficiency Syndromes 6: 249-264, 1993.

Ganem D. Human herpesvirus 8; an overview. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract L5, 1998.

Gao S-J et al. Seroconversion to antibodies against Kaposi's sarcoma associated herpesvirus-like latent nuclear antigens before the development of Kaposi's sarcoma. New England Journal of Medicine 335: 233-241, 1996.

Gill PS et al. Advanced AIDS-related Kaposi's sarcoma: Results of pilot studies using combination chemotherapy. Cancer 65: 1074-1079, 1990.

Gill PS et al. Systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomized trial. American Journal of Medicine 90: 427-433, 1991.

Gill PS et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. Journal of Clinical Oncology 14(8): 2353-2364, 1996.

Gill PS et al. The effects of preparations of human chorionic gonadotrophin on AIDS-related Kaposi's sarcoma. New England Journal of Medicine 335(17): 1261-1269, 1996b.

Gill PS et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. Journal of Clinical Oncology 17(6): 1876-1883, 1999.

Glesby MJ et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. Journal of Infectious Diseases 173(6): 1477-1480, 1996.

Goebel FD et al. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. British Journal of Cancer 73(8): 989-994, 1996.

Groopman JE et al. Interferon therapy for Kaposi's sarcoma associated with AIDS. Ann Intern Med 110: 335-337, 1989.

Grulich A et al. Route of transmission of Kaposi's sarcoma associated herpes virus. J Acquir Immune Defic Syndr 14: A16, 1997.

Guihot A et al. Pulmonary manifestations of Castleman's disease in patients with HIV infection. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, abstract 934, 2003.

Harris PJ et al. Treatment of Kaposi's sarcoma and other manifestations of AIDS with human chorionic gonadotrophin. Br Med J 346: 118-119, 1995.

Haverkos G et al. Health hazards of nitrite inhalants. National Institute of Drug Abuse Research Monograph 83, 1988.

Haverkos HW et al. Nitrite inhalant abuse and AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 3: 547-550, 1990.

He J et al. Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother-child pairs with KS. Journal of Infectious Diseases 178(6): 1787-1790, 1998.

Hermans P et al. Epidemiology, etiology and pathogenesis, clinical presentations and therapeutic approaches in Kaposi's sarcoma: 5-year lessons from AIDS. Biomedicine and Pharmacotherapy 52(10): 444-446, 1998.

Hermans P et al. AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations. Journal of Human Virology 1(2): 82-89, 1998b.

Hessol NA et al. Cancer risk among participants in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 36: 978-985, 2004.

Hladik W et al. Human herpesvirus 8 infection among voluntary blood donors in Uganda. Thirteenth International AIDS Conference, Durban, abstract A475, 2000.

Holkova B et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. Journal of Clinical Oncology 19(18): 3848-3851, 2001.

Hosseinipour M et al. Experience with treatment of Kaposi's sarcoma patients in Lilongwe, Malawi. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 782, 2004.

Huang YQ et al. HPV-16 related DNA sequences in Kaposi's sarcoma. Lancet 339: 515-518, 1992.

Huang YQ et al. Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 345: 759-761, 1995.

Ingber D et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557, 1990.

Jacob J et al. AIDS-related Kaposi's sarcoma: concepts of care. Seminars in Oncology Nursing 5(4): 263-275, 1989.

Jacobson LP et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndromes 21(suppl 1): S34-41, 1999.

Jones JL et al. AIDS-associated Kaposi's sarcoma. Science 267(5201): 1088-1089, 1995.

Kaldor JM et al. Factors associated with Kaposi's sarcoma in a cohort of homosexual and bisexual men. Journal of Acquired Immune Deficiency Syndromes 6: 1145-1149, 1993.

Kovacs J et al. Combined zidovudine and interferon-alpha therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 111(4): 280-287, 1989.

Krown S et al. Interferon alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi's sarcoma with the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 112: 812-821, 1990.

Krown S et al. Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: a Phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS. Journal of Clinical Oncology 10: 1344-1351, 1992.

Krown SE. The role of interferon in the therapy of epidemic Kaposi's sarcoma. Seminars in Oncology 14 (suppl 3): 27-33, 1987.

Krown SE. Treatment of AIDS-associated malignancy. Cancer Detection and Prevention 14(3): 405-409, 1990.

La Duca JR et al. Detection of human herpes virus 8 DNA sequences in tissues and bodily fluids. Journal of Infectious Disease 178:6: 1610-1615, 1998.

Lassoued K et al. Treatment of the acquired immune deficiency syndrome-related Kaposi's sarcoma with bleomycin as a single agent. Cancer 66: 1869-1872, 1990.

Laubenstein LJ et al. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine. Journal of Clinical Oncology 2: 1115-1120, 1984.

Leao JC et al. Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients. Journal of Medical Virology 62: 416-420, 2000.

Ledergerber B et al. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. British Medical Journal 319(7201): 23-24, 1999.

Leoung GS et al. Treatment of Kaposi's sarcoma using Targretin (LGD0169), a topical retinoid gel. Eleventh International Conference on AIDS, Vancouver, abstract We.B.3241, 1996.

Liestoel K at al. Kaposi's sarcoma and protection from HIV dementia. Science 280: 361-362, 1998.

Lilenbaum RC et al. Systemic treatment of Kaposi's sarcoma: current status and future directions. AIDS 8: 141-151, 1994.

Lin J-C et al. Is Kaposi's-sarcoma-associated herpesvirus detectable in semen of HIV-infected homosexual men? Lancet 346(8990): 1601, 1995.

Little RF et al. Interleukin 12 (IL-12) appears to be active in AIDS-associated Kaposis sarcoma (KS): early results of a pilot study. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 5, 2000.

Little RF et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. Journal of Clinical Oncology 18(13): 2593-2602, 2000b.

Little RF et al. Preliminary results of combination liposomal doxorubicin and interleukin-12 followed by chronic IL-12 maintenance therapy in advanced AIDS-related Kaposis sarcoma. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 816, 2003.

Lyter DW et al. Temporal relationship of changes in plasma HIV RNA levels and clinical progression or regression of Kaposi's sarcoma. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 433, 1998.

Martin JN et al. Sexual transmission and the natural history of human herpesvirus 8 infection. New England Journal of Medicine 338(14): 948-954, 1998.

Martin-Carbonero L et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 18: 1737-1739, 2004.

Martinez V et al. Prognostic factors of Kaposi's sarcoma in the era of HAART. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris (Antiviral Therapy 8:1), abstract 78, 2003.

Martinez V et al. Prognostic factors of Kaposi's sarcoma in the HAART era. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 779, 2004.

Mbulaiteye S et al. Bloodborne transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in children with sickle cell disease. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 811, 2003.

Melbye M. Risk factors for HHV-8 seropositivity and progression to Kaposi's sarcoma in a cohort of homosexual men, 1981-96. Journal of Acquired Immune Deficiency Syndromes 14(4): A16, 1997.

Miles S et al. Anti-tumor activity of oral 9-cis-retinoic acid in AIDS related Kaposi's sarcoma: AIDS Malignancy Consortium Study 002. 12^th World AIDS Conference, Geneva, abstract 22276, 1998.

Miles S et al. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma derived cells. Science 255: 1432-1434, 1992.

Miles SA et al. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 112: 582-589, 1992b.

Mitsuyasu RT et al. The role of cytokines and cytokine inhibitors in AIDS-related Kaposi's sarcoma. Second International Congress on Drug Therapy in HIV Infection, Glasgow, abstract 13.5, 1994.

Mitsuyasu RT. Interferon-alpha in the treatment of AIDS-related Kaposi's sarcoma. British Journal of Haematology 79(Suppl 1): 69-73, 1991.

Mocroft A et al. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. AIDS 10(10): 1101-1105, 1996.

Mocroft A et al. The changing pattern of Kaposi's sarcoma in patients with HIV, 1994-2003: the EuroSIDA study. Cancer 100: 2644-2654, 2004.

Monini P et al. Kaposi's sarcoma-associated herpes virus DNA sequences in prostate tissue and human semen. New England Journal of Medicine 334: 1168-1172, 1996.

Monticelli A et al. Regression of AIDS-related Kaposi's sarcoma following combined antiretroviral treatment. Revista Argentina de Microbiologia 32(4): 206-208, 2000.

Moore PS et al. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. New England Journal of Medicine 332(18): 1181-1185, 1995.

Morfeldt L et al. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scandinavian Journal of Infectious Disease 26: 749-752, 1994.

Nair B et al. Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as Oncostatin M. Science 255: 1430-1432, 1992.

Nakamura S et al. Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial wall complex [SP-PG]. Science 255: 1437-1440, 1992.

Nasti G et al. AIDS-associated Kaposi's sarcoma is more aggressive in women: a study of 54 patients. Journal of Acquired Immune Deficiency Syndromes and Human Retroviruses 20(4): 337-341, 1999.

Nasti G et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. Journal of Clinical Oncology 18(7): 1550-1557, 2000.

Nasti G et al. AIDS-related Kaposi's sarcoma in 211 patients: assessment of the AIDS Clinical Trial Group staging classification prognostic value in the era of HAART. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 815, 2003.

Neuville S et al. Failure of anti-CD20 monoclonal antibody (rituximab) to control exacerbation of HIV-associated multicentric Castleman's disease in HIV-infected patients. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris (Antiviral Therapy 8:1), abstract 926, 2003.

Newell M et al. DOX-SL maintenance therapy after response in AIDS-related Kaposi's sarcoma. Third International Congress on Drug Therapy in HIV Infection, Birmingham, abstract P133, 1996.

Newman S et al. Treatment of epidemic Kaposi's sarcoma with intralesional vinblastine injection. Proceedings of the American Society for Clinical Oncology 19: abstract, 1988.

Northfelt DW et al. Doxil as first-line therapy of AIDS-related KS: Integrated efficacy and safety results from two comparative trials. Fourth Conference on Retroviruses and Opportunistic Infections, Washington, abstract 736, 1997.

Northfelt DW et al. Pegylated doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. Journal of Clinical Oncology 16(&): 2445-2451, 1998.

Nunez M et al. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clinical Trials 2(5): 429-437, 2001.

O'Brien TR et al. Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: rates, risk factors and relationship to Kaposi's sarcoma. Journal of Infectious Diseases 180(4): 1010-1017, 1999.

O'Brien TR et al. Relationship between Kaposi sarcomaassociated herpesvirus and HIV (letters). Journal of the American Medical Association 287(12): 1525-1528, 2002.

Oksenhendler S et al. Multicentric Castleman's disease in 70 HIV-infected patients: a prospective cohort study. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris (Antiviral Therapy 8:1), abstract 74, 2003.

Osmond DH et al. Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. Journal of the American Medical Association 287(2): 221-225, 2002.

Pauk J et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 343: 1369-1377, 2000.

Peterman TA et al. Epidemiologic clues to the etiology of Kaposi's sarcoma. AIDS 7: 605-611, 1993.

Peterman TA. Kaposi's sarcoma and exposure to faeces. Lancet 339: 685-686, 1992.

Phiri S et al. Human herpesvirus type 8/Kaposi's sarcoma-associated herpesvirus infection in Zambian children: correlation with HIV-1 status. Eleventh Conference on Retroviruses and Opportunisitic Infections, San Francisco, abstract 781, 2004.

Pluda JM et al. A pilot/dose-finding study of interleukin 12 (IL-12) administered to patients with AIDS-associated Kaposi's sarcoma. 35^th Annual Meeting of the American Society of Clinical Oncology, Atlanta, abstract 2111, 1999.

Presant CA. Liposomal anthracycline therapy of Kaposi's sarcoma (KS). Overview of pilot and multicenter phase 2 trials. Second International Congress on Drug Therapy in HIV Infection, Glasgow, abstract 13.4, 1994.

Quivey JM et al. Radiotherapy for the treatment of AIDS-related Kaposi's sarcoma: an updated analysis. Sixth International Conference on AIDS, San Francisco, abstract 2181, 1990.

Rabkin CS et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. New England Journal of Medicine 336: 988-993, 1997.

Rady PL et al. Herpesvirus-like DNA sequences in non-Kaposi's sarcoma skin lesions of transplant patients. Lancet 345: 1339-1340, 1995.

Renato M et al. Effects of HAART regimens as exclusive treatment of slow proliferating Kaposis sarcoma. Thirteenth International AIDS Conference, Durban, abstract TuOrB302, 2000.

Rosenthal E et al. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. American Journal of Clinical Oncology 25(1): 57-59, 2002.

Rozenbaum W et al. Long-term follow-up of 120 patients with AIDS-related Kaposi's sarcoma treated with interferon alpha-2a. Journal of Investigative Dermatology 95(6): 161s-165s, 1990.

Saiag P et al. Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized phase II trial. Kaposi's Sarcoma ANRS Study Group. Agence Nationale de Recherches sur le SIDA. AIDS 12(16): 2169-2176, 1998.

Santambrogio S et al. Effect of highly active antiretroviral treatment (HAART) in patients with AIDS-associated Kaposi's sarcoma (KS). Twelfth World AIDS Conference, Geneva, abstract 22275, 1998.

Saville MW et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346(8966): 26-28, 1995.

Schwartsmann G et al. Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma. Tumori 82(4): 360-363, 1996.

Schwartsmann G et al. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy. Journal of Clinical Oncology 15(5): 2118-2124, 1997.

Sgadari C et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Medicine 8(3): 225-232, 2002.

Shepherd FA et al. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. Journal of Clinical Oncology 16(5): 1736-1742, 1998.

Sidky TA et al. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Research 47: 5155-5161, 1987.

Soderberg LSF et al. Increased tumour growth in mice exposed to inhaled isobutyl nitrite. Toxicology Letters 104: 35-41, 1999.

Staddon et al. A randomized dose finding study of recombinant platelet fact 4 (rPF4) in cutaneous AIDS-related Kaposi's sarcoma (KS). Proceedings of the American Society for Clinical Oncology 13: 50, 1994.

Stewart S et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. Journal of Clinical Oncology 16(2): 683-691, 1998.

Su I-J et al. Herpesvirus-like DNA sequence in Kaposi's sarcoma from AIDS and non-AIDS patients in Taiwan. Lancet 345: 722-723, 1995.

Tam HK et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposis sarcoma or non-Hodgkins lymphoma. International Journal of Cancer 98(6): 916-922, 2002.

Thirlwell C et al. Kaposi's sarcoma in the third millenium. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris (Antiviral Therapy 8:1), abstract 933, 2003.

Thommes J et al. Phase II study (protocol L1057-28) of Panretin capsules (LGD1057, ALRT1057) for AIDS-related Kaposi's sarcoma. 12th World AIDS Conference, Geneva, abstract 22278, 1998.

Tirelli U et al. Impact of HAART on the clinical management of AIDS-related cancers. European Journal of Cancer 37(10): 1320-1324, 2001.

Tran DC et al. Inhalant nitrite exposure alters mouse hepatic angiogenic gene expression. Biochem Biophys Res Commun 310: 439-445, 2003.

Tulpule A et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. Journal of Clinical Oncology 18(4): 716-723, 2000.

Uthayakumar S et al. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. AIDS 10(5): 515-519, 1996.

Vaccher E et al. Multicentric Castleman disease (MCD) in 16 patients with HIV infection: a sudy of the GICAT (Italian Cooperative Group on AIDS and Tumors). 35th Annual Meeting of the American Society of Clinical Oncology, Atlanta, abstract 62, 1999.

Vaithilingum M et al. Prevalence and patterns of antibody response to human herpes virus 8 (HHV-8) in mother-baby pairs in KwaZulu Natal, South Africa. Thirteenth International AIDS Conference, Durban, abstract A471, 2000.

Viera J et al. Transmissible KSHV in saliva. Fourth Conference on Retroviruses and Opportunistic Infections, Washington, abstract 729, 1997.

Vogel J et al. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma lesions in transgenic mice. Nature 335: 606-611, 1988.

Walmsley S et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical aliretinoin (9-cis-retinoic acid) gel. Journal of Acquired Immune Deficiency 22(3): 235-246, 1999.

Welles L et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. Journal of Clinical Oncology 16(3): 1112-1121, 1998.

Wellstein A et al. Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulphate. Journal of the National Cancer Institute 83: 716-722, 1991.

Yarchoan R et al. Recent advances in therapy of Kaposi's sarcoma. Sixth Conference on Retrovirusess and Opportunistic Infections, Chicago, abstract S17, 1999.

Yegorov O et al. Genetic evidence of vertical transmission of Kaposis sarcoma-associated herpesvirus (human herpesvirus 8) in Zambian families. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 810, 2003.

Zietz C et al. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. Correspondence. New England Journal of Medicine 340(24): 1923-1924, 1999.